Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer

被引：0
作者：
Wehbe, TW [1 ]
Stein, BS [1 ]
Akerley, WL [1 ]
机构：
[1] RHODE ISL HOSP,DEPT UROL,PROVIDENCE,RI 02902
来源：
MAYO CLINIC PROCEEDINGS | 1997年 / 72卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of disease state, and introduction of a possible source of error in clinical trials, In this case report, we describe a patient with HRPC whose prostate-specific antigen levels decreased substantially in response to withdrawal of megestrol acetate. Such a response should be considered when megestrol acetate is used in the treatment of HRPC.
引用
收藏
页码：932 / 934
页数：3
相关论文
共 50 条
  • [1] Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
    Sartor, O
    Weinberger, M
    Moore, A
    Li, AL
    Figg, WD
    UROLOGY, 1998, 52 (02) : 252 - 256
  • [2] Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    Smith, DC
    Dunn, RL
    Strawderman, MS
    Pienta, KJ
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1835 - 1843
  • [3] Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer
    D'Amico, AV
    Chen, MH
    Cox, MC
    Dahut, W
    Figg, WD
    UROLOGY, 2005, 66 (03) : 571 - 576
  • [4] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Yang, Yi-Chun Ou
    Carducci, Michael A.
    Tannock, Ian
    de Wit, Ronald
    Eisenberger, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3965 - 3970
  • [5] EVALUATION OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE MARKER FOR RESPONSE OF HORMONE-REFRACTORY PROSTATE-CANCER TO SURAMIN THERAPY
    SRIDHARA, R
    EISENBERGER, MA
    SINIBALDI, VJ
    REYNO, LM
    EGORIN, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) : 2944 - 2953
  • [6] PROSTATE-SPECIFIC ANTIGEN AS A MEASURE OF DISEASE OUTCOME IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER
    KELLY, WK
    SCHER, HI
    MAZUMDAR, M
    VLAMIS, V
    SCHWARTZ, M
    FOSSA, SD
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 607 - 615
  • [7] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    UROLOGY, 2006, 68 (03) : 565 - 569
  • [8] Outcome of patients with hormone-refractory prostate cancer: Prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen
    Tomioka, Susumu
    Shimbo, Masashi
    Amiya, Yoshiyasu
    Nakatsu, Hiroomi
    Murakami, Shino
    Shimazaki, Jun
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) : 36 - 42
  • [9] Economic impact of prostate-specific antigen doubling time in patients with hormone-refractory prostate cancer
    Mulani, P
    Botteman, M
    Hay, JW
    Cifaldi, M
    VALUE IN HEALTH, 2005, 8 (03) : 346 - 346
  • [10] Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma
    Fujikawa, K
    Matsui, Y
    Fukuzawa, S
    Takeuchi, H
    EUROPEAN UROLOGY, 2000, 37 (02) : 218 - 222
12345